• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 30, 2016 Category: Hematology Authors: Hannah Cohen, Deepa Jayakody Arachchillage, Saskia Middeldorp, Jan Beyer‐Westendorf, Rezan Abdul Kadir Tags: Recommendations and Guidelines Source Type: research

The effect of carbamazepine on warfarin anticoagulation: a register‐based nationwide cohort study involving the Swedish population
ConclusionsFour out of five warfarin‐treated patients initiating co‐medication with carbamazepine experienced subtherapeutic anticoagulative effect within 3‐5 weeks. The warfarin dose was subsequently increased by 49%, a change that differed widely between patients. In order to avoid thrombosis and ischaemic stroke, the initiation of carbamazepine should be accompanied by close INR monitoring to better meet the anticipated increase in dose demand.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 1, 2016 Category: Hematology Authors: Buster Mannheimer, Marine L. Andersson, Hans Järnbert Pettersson, Jonatan D. Lindh Tags: Original Article ‐ Coagulation Source Type: research

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)
ConclusionsIn this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120 mg daily darexaban group compared with warfarin with a reduction in plasma D‐dimer as marker for hemostasis. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered.
Source: Journal of Thrombosis and Haemostasis - July 15, 2015 Category: Hematology Authors: G. Y. H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm Tags: Original Article Source Type: research

A Phase II, Double‐Blind, Randomized, Parallel Group, Dose Finding Study of the Safety and Tolerability of Darexaban Compared with Warfarin in Patients with Non‐Valvular Atrial Fibrillation
ConclusionsIn this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120mg daily dose group of darexaban compared to warfarin and plasma D‐dimer as marker for haemostasis was reduced. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2015 Category: Hematology Authors: Gregory YH Lip, Jonathan L Halperin, Palle Petersen, George M Rodgers, Denes Pall, Ronny W Renfurm Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights form the RE‐LY trial
ConclusionsAnemia is associated with a raised risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - February 1, 2015 Category: Hematology Authors: B. Daan Westenbrink, Marco Alings, Stuart J. Connolly, John Eikelboom, Michael D. Ezekowitz, Jonas Oldgren, Sean Yang, Janice Pongue, Salim Yusuf, Lars Wallentin, W.H. Gilst Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non‐valvular atrial fibrillation patients: a multicenter propensity‐matched analysis
ConclusionsThe heparin‐bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients.
Source: Journal of Thrombosis and Haemostasis - January 7, 2015 Category: Hematology Authors: T.‐H. Kim, J.‐Y. Kim, H.‐S. Mun, H.‐Y. Lee, Y. H. Roh, J.‐S. Uhm, H.‐N. Pak, M.‐H. Lee, B. Joung Tags: Original Article Source Type: research

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: A multicenter propensity‐matched analysis
ConclusionsThe heparin bridging therapy increased bleeding without the benefit of preventing stroke at the initiation of OAC in NVAF. Our data suggest that heparin bridging should not be considered at the initiation of OAC in NVAF patients.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Tae‐Hoon Kim, Jong‐Youn Kim, Hee‐Sun Mun, Hye‐Young Lee, Yun Ho Roh, Jae‐Sun Uhm, Hui‐Nam Pak, Moon‐Hyoung Lee, Boyoung Joung Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Comparing mortality in patients with atrial fibrillation who are receiving a direct‐acting oral anticoagulant or warfarin: a meta‐analysis of randomized trials
ConclusionAs compared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all‐cause mortality, vascular mortality, and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular‐related and bleeding‐related mortality, which, in turn, may be related to the reduction in intracranial bleeding.
Source: Journal of Thrombosis and Haemostasis - July 25, 2014 Category: Hematology Authors: A. Liew, M. O'Donnell, J. Douketis Tags: Brief Report Source Type: research

D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
ConclusionIn anticoagulated patients with AF the level of D‐dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D‐dimer level.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christina Christersson, Lars Wallentin, Ulrika Andersson, John H Alexander, Jack Ansell, Raffaele Caterina, Bernard J Gersh, Christopher B Granger, Michael Hanna, John D Horowitz, Kurt Huber, Steen Husted, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Prothrombin Complex Concentrate (PCC) for Non‐Vitamin K Oral Anticoagulant (NOAC) reversal: Good enough for now?
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2014 Category: Hematology Authors: Mike Makris Tags: Commentary Source Type: research

Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta‐analysis of Randomized Trials
ConclusionCompared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all‐cause mortality, vascular mortality and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular‐ and bleeding‐related mortality which, in turn, may be related to the reduction in intracranial bleeding.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2014 Category: Hematology Authors: A. Liew, M. O'Donnell, J. Douketis Tags: Brief Report ‐ Coagulation Source Type: research

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐AF study
ConclusionIf anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose‐adjusted warfarin, with a lower bleeding risk.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: H.R. Buller, J. Halperin, G.J. Hankey, G. Pillion, M.H. Prins, G.E. Raskob Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for hemorrhagic stroke.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: J.‐C. Lega, P. Mismetti, M. Cucherat, T. Fassier, L. Bertoletti, C. Chapelle, S. Laporte Tags: Original Article Source Type: research

Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of new OACs holds promise for reducing the risk of systemic thromboembolism, but specific data are still limited.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: L. V. Andersen, G. Y. H. Lip, J. S. Lindholt, L. Frost Tags: Original Article Source Type: research

Impact of double‐blind versus open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for haemorrhagic stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: Jean‐Christophe Lega, Patrick Mismetti, Michel Cucherat, Thomas Fassier, Laurent Bertoletti, Céline Chapelle, Silvy Laporte Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Pages: 1  2